Physician profile
David L Spangler
NPI 1093774309
$2,147.23
in general payments reported to CMS, 2019-2025
33 companies · $408 in 2025
The $408 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.48 · 2020: $236 · 2021: $373 · 2022: $315 · 2023: $509 · 2024: $259 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $381.10 | 2020-2024 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $337.01 | 2021-2025 | |
| Astellas Pharma US INC | $115.12 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $96.04 | 2023-2024 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $95.45 | 2020-2025 | |
| Hologic Sales and Service, LLC | $88.70 | 2020-2025 | Aptima |
| Shield Therapeutics INC | $83.06 | 2023-2025 | Accrufer |
| Mylan Pharmaceuticals INC. | $79.27 | 2020-2022 | |
| Scynexis, INC. | $77.78 | 2022 | |
| Organon LLC | $66.42 | 2023-2024 | Jada System, Nexplanon |
| Roche Diagnostics Corporation | $66.20 | 2019-2021 | |
| Novo Nordisk INC | $64.53 | 2023-2024 | Wegovy |
| Amgen INC. | $49.66 | 2020-2021 | |
| Urovant Sciences INC | $48.73 | 2022 | |
| Coopersurgical, INC. | $45.52 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $40.93 | 2021-2022 | |
| Baxter Healthcare | $40.47 | 2025 | Perclot |
| Intuitive Surgical, INC. | $39.10 | 2023 | Da Vinci Surgical System |
| Pharmacosmos Therapeutics INC. | $34.10 | 2025 | Monoferric |
| Pfizer INC. | $33.63 | 2023-2024 | |
| Agile Therapeutics, INC. | $31.38 | 2021 | |
| Sage Therapeutics, LLC | $30.49 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $28.49 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.28 | 2022 | |
| Exact Sciences Corporation | $21.30 | 2025 | The Cologuard Plus Collection Kit |
| Davol INC. | $20.85 | 2020 | |
| Ethicon US, LLC | $20.84 | 2024 | Enseal |
| Meditrina | $16.59 | 2022 | |
| Minerva Surgical, INC | $16.54 | 2023 | |
| Merck Sharp & Dohme LLC | $16.41 | 2023 | Gardasil 9 |
| Axonics, INC. | $14.69 | 2023 | Axonics |
| Exeltis, USA INC. | $11.32 | 2020 | |
| Lupin INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.